Australia markets closed

Vertex Pharmaceuticals Incorporated (0QZU.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
392.91-2.14 (-0.54%)
As of 07:11PM BST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.37
52-week change 337.54%
S&P500 52-week change 321.61%
52-week high 3446.29
52-week low 30.00
50-day moving average 3424.38
200-day moving average 3373.25

Share statistics

Avg vol (3-month) 32.91k
Avg vol (10-day) 31.2k
Shares outstanding 5255.56M
Implied shares outstanding 6N/A
Float 8257.56M
% held by insiders 10.11%
% held by institutions 197.27%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 36.68%
Operating margin (ttm)37.97%

Management effectiveness

Return on assets (ttm)13.17%
Return on equity (ttm)22.99%

Income statement

Revenue (ttm)9.87B
Revenue per share (ttm)38.30
Quarterly revenue growth (yoy)9.30%
Gross profit (ttm)N/A
EBITDA 4.48B
Net income avi to common (ttm)3.62B
Diluted EPS (ttm)9.48
Quarterly earnings growth (yoy)18.30%

Balance sheet

Total cash (mrq)11.22B
Total cash per share (mrq)43.43
Total debt (mrq)808.4M
Total debt/equity (mrq)4.60%
Current ratio (mrq)3.99
Book value per share (mrq)68.22

Cash flow statement

Operating cash flow (ttm)3.54B
Levered free cash flow (ttm)3.51B